Senior Director, Translational Medicine
cAMPfield Therapeutics
Senior Director, Translational Medicine
cAMPfield Therapeutics
Develops oral PDE4 inhibitors for IBD
Department: Research & Development
Reports To: President, Research & Development
Location: Boston, MA (Hybrid)
cAMPfield is a clinical-stage biopharmaceutical company focused on developing well-tolerated and highly effective oral medicines, founded and led by industry veterans with success developing therapies for immune-mediated inflammatory diseases, including inflammatory bowel disease (IBD).
Prifemilast is an investigational, potentially best-in-class, once-daily oral preferential PDE4B inhibitor designed to set a new standard of care for IBD. Prifemilast has been well-tolerated in more than 1000 clinical trial participants to date and has demonstrated robust efficacy in Phase 3 trials for plaque psoriasis. Many clinicians and patients prefer the convenience and familiarity of oral therapies, but currently approved oral treatments for IBD are limited by poor tolerability, safety concerns, or modest efficacy. Prifemilast offers the potential to combine the convenience of an oral therapy with the safety and efficacy that patients deserve.
cAMPfield was founded by a team with a track record of developing category-defining IBD and immunology therapies, and launched with a $180 million Series A to advance prifemilast through registration-enabling trials. We have offices in San Diego, CA and Boston, MA.
cAMPfield is seeking a Senior Director of Translational Medicine to build and lead the translational strategy connecting prifemilast's mechanism of action (PDE4B-selective inhibition and cAMP-mediated modulation of mucosal inflammation) to clinical outcomes in IBD This leader will design and oversee the biomarker, endoscopic, histologic, and pharmacodynamic strategy across our clinical portfolio, and will play a central role in informing dose selection, patient stratification, and mechanistic differentiation versus other IBD therapies. This is a senior, highly visible role reporting into R&D leadership with regular exposure to the executive team and board.
To apply, please submit your resume/CV and a brief note on your interest in cAMPfield's mission to [email protected].
cAMPfield Therapeutics is an equal opportunity employer. We are committed to building a diverse team and an inclusive culture, and we welcome applicants of all backgrounds regardless of race, color, religion, sex, sexual orientation, gender identity, national origin, age, disability, veteran status, or any other protected characteristic.
Develops oral PDE4 inhibitors for IBD
cAMPfield Therapeutics develops oral small-molecule therapies for inflammatory and immunological diseases. Its lead program, prifemilast, is an oral PDE4 inhibitor being developed for inflammatory bowel disease (IBD), including ulcerative colitis. The drug’s mechanism targets PDE4 to reduce inflammation, and prifemilast has shown efficacy in Phase 2 studies for ulcerative colitis. The company focuses on in-licensing assets with potential to transform patient care and aims to establish prifemilast as a preferred IBD treatment with a favorable safety profile. Global rights to prifemilast (also known as HPP737) were acquired from vTv Therapeutics and Newsoara Biopharma. cAMPfield recently launched with a $180 million Series A led by top-tier investors, signaling growth plans and potential partnerships. The company’s goal is to bring a best-in-class oral PDE4 inhibitor to patients and pursue collaborations that advance its clinical programs.
Explore more opportunities at cAMPfield Therapeutics